Seroprevalence of Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 Among Healthcare Workers in Kenya.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Etyang Anthony O, Lucinde Ruth, Karanja Henry, Kalu Catherine, Mugo Daisy, Nyagwange James, Gitonga John, Tuju James, Wanjiku Perpetual, Karani Angela, Mutua Shadrack, Maroko Hosea, Nzomo Eddy, Maitha Eric, Kamuri Evanson, Kaugiria Thuranira, Weru Justus, Ochola Lucy B, Kilimo Nelson, Charo Sande, Emukule Namdala, Moracha Wycliffe, Mukabi David, Okuku Rosemary, Ogutu Monicah, Angujo Barrack, Otiende Mark, Bottomley Christian, Otieno Edward, Ndwiga Leonard, Nyaguara Amek, Voller Shirine, Agoti Charles N, Nokes David James, Ochola-Oyier Lynette Isabella, Aman Rashid, Amoth Patrick, Mwangangi Mercy, Kasera Kadondi, Ng'ang'a Wangari, Adetifa Ifedayo M O, Wangeci Kagucia E, Gallagher Katherine, Uyoga Sophie, Tsofa Benjamin, Barasa Edwine, Bejon Philip, Scott J Anthony G, Agweyu Ambrose, Warimwe George M
Аннотация
METHODS: We recruited 684 HCWs from Kilifi (rural), Busia (rural), and Nairobi (urban) counties. The serosurvey was conducted between 30 July and 4 December 2020. We tested for immunoglobulin G antibodies to SARS-CoV-2 spike protein, using enzyme-linked immunosorbent assay. Assay sensitivity and specificity were 92.7 (95% CI, 87.9-96.1) and 99.0% (95% CI, 98.1-99.5), respectively. We adjusted prevalence estimates, using bayesian modeling to account for assay performance.
RESULTS: The crude overall seroprevalence was 19.7% (135 of 684). After adjustment for assay performance, seroprevalence was 20.8% (95% credible interval, 17.5%-24.4%). Seroprevalence varied significantly (P < .001) by site: 43.8% (95% credible interval, 35.8%-52.2%) in Nairobi, 12.6% (8.8%-17.1%) in Busia and 11.5% (7.2%-17.6%) in Kilifi. In a multivariable model controlling for age, sex, and site, professional cadre was not associated with differences in seroprevalence.
CONCLUSION: These initial data demonstrate a high seroprevalence of antibodies to SARS-CoV-2 among HCWs in Kenya. There was significant variation in seroprevalence by region, but not by cadre.